TABLE 2.

Comparison of sensitivities and specificities for the VlsE and C6 assays for the detection of B. burgdorferi antibodies

Patient group	n	VlsE assay				C6 assay				WB
		No. with result of:		Sen.c (%)	Spe.d (%)	No. with result of:		Sen. (%)	Spe. (%)	No. with result of:		Sen. (%)	Spe. (%)
		+	−			+	−			+	−
CDC panel I (culture confirmed)
Early localized diseasea	19	13	6	68.4		11	8	57.9		9	10	47.4
Early disseminated diseaseb	41	31	10	75.6		33	8	80.5		31	10	75.6
CDC panel II
Healthy	5	0	5		100.0	0	5		100.0	0	5		100.0
Early disease (<2 mo)	26	16	10	61.5		20	6	76.9		17	9	65.4
Late disease (>2 mo)	11	11	0	100.0		11	0	100.0		11	0	100.0
Non-LD
CMV	20	0	20		100.0	0	20		100.0
EBV	20	0	20		100.0	0	20		100.0
HAMA positive	10	2	8		80.0	1	9		90.0
Healthy, nonendemice	300	2	298		99.3	7	293		97.7
Healthy, endemicf	300	1	299		99.7	2	298		99.3
Helicobacter pylori	20	1	19		95.0	0	20		100.0
HIV	20	0	20		100.0	0	20		100.0
LYMErix vaccine	11	0	11		100.0	0	11		100.0
Multiple sclerosis	8	0	8		100.0	0	8		100.0
Rheumatoid arthritis	20	2	18		90.0	2	18		90.0
RF positive	10	0	10		100.0	0	10		100.0
Syphilis patients	18	0	18		100.0	0	18		100.0
Systemic lupus erythematosus	20	0	20		100.0	0	20		100.0
Tick-borne relapsing fever	10	7	3		30.0	4	6		60.0
Various autoimmune diseases (e.g., systemic sclerosis, Sjögren's syndrome)	20	1	19		95.0	1	19		95.0
Total	807	16	791		98.0	17	790		97.9

^aNine collected at baseline presentation, 10 collected 1 to 3 weeks after presentation and treatment.

^bTwelve collected at baseline presentation, 29 collected 1 to 3 weeks after presentation and treatment.

^cSen., sensitivity.

^dSpe., specificity.

^eSubjects from an area where LD is not endemic.

^fSubjects from an area where LD is endemic.